SPIN1 and myeloid sarcoma: Among the 43 AA MS patients studied, we identified early repleters that included two patients with high concentrations of anti-OCR antibodies (4.6%), which was higher than the 0.4% prevalence reported in a clinical randomized trial with patients of diverse ethnicities and races (6).